Table 1. Clinical characteristics of the three patient groups.
| Control (n = 13) | CAD (n = 19) | ACS (n = 16) | P value | |
| Gender [m/f] | 13/0 | 19/0 | 16/0 | NS |
| Age [years] | 59±3.8 | 59.8±3.8 | 58.7±4.3 | NS |
| Systolic BD [mmHg] | 132±9 | 135±14 | 135±21 | NS |
| Diastolic BD [mmHg] | 79±10 | 78±7 | 84±16 | NS |
| BMI [kg/m2] | 27.1±4.2 | 28.0±4.2 | 27.6±5.1 | NS |
| Total cholesterol [mmol/L] | 4.6±1.2 | 4.3±0.7 | 5.3±1.1 | <0.05* |
| LDL cholesterol [mmol/L] | 2.6±1.2 | 2.5±0.6 | 3.5±0.9 | <0.05* |
| HDL cholesterol [mmol/L] | 1.4±0.4 | 1.1±0.2 | 1.1±0.2 | <0.05†,‡ |
| CRP [mg/L] | 1.4±1.0 | 2.4±3.2 | 8.4±9.3 | <0.05* |
| Adipositas | 3 (23.1) | 5 (26.3) | 4 (25.0) | NS |
| Dyslipidemia | 4 (30.8) | 10 (52.6) | 9 (52.9) | <0.05†,‡ |
| Hypertension | 5 (38.5) | 11 (57.9) | 11 (64.7) | <0.05†,‡ |
| Current smoking | 3 (23.1) | 3 (15.8) | 7 (41.2) | <0.05* |
| Aspirin | 6 (46.2) | 14 (73.7) | 14 (73.7) | <0.05†,‡ |
| Clopidogrel | 0 (0) | 7 (36.8) | 7 (36.8) | <0.05†,‡ |
| Beta-Blocker | 4 (30.8) | 9 (47.4) | 9 (47.4) | NS |
| ACEI/ATB | 6 (46.2) | 9 (47.4) | 9 (47.4) | NS |
| Statins | 5 (38.5) | 13 (68.4) | 13 (68.4) | <0.05†,‡ |
| Diuretics | 2 (15.4) | 3 (15.8) | 3 (15.8) | NS |
*
0.05* CADnts with CAD and ACS,ACS group)erosclerosis looses its cardioprotectice properties.**
*
ACS vs CAD.
†
Healthy vs CAD.
‡
Healthy vs ACS.